Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Chou

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab VedotinCarissa E Chu, Martin Sjöström, Emily A Egusa, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
European Urology Oncology|June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± PembrolizumabKevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Cardiovascular Research|October 25, 2014
E2F1 suppresses cardiac neovascularization by down-regulating VEGF and PlGF expressionMin Wu, Junlan Zhou, Min Cheng, et al.
Nature Communications|June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expressionHeiko Yang, Hanbing Song, Elizabeth Yip, et al.
Nature Communications|July 30, 2021
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancerRajdeep Das, Martin Sjöström, Raunak Shrestha, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab VedotinCarissa E Chu, Martin Sjöström, Emily A Egusa, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
European Urology Oncology|June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± PembrolizumabKevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Cardiovascular Research|October 25, 2014
E2F1 suppresses cardiac neovascularization by down-regulating VEGF and PlGF expressionMin Wu, Junlan Zhou, Min Cheng, et al.
Nature Communications|June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expressionHeiko Yang, Hanbing Song, Elizabeth Yip, et al.
Nature Communications|July 30, 2021
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancerRajdeep Das, Martin Sjöström, Raunak Shrestha, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Pageof 9